Biogen inc. (BIIB)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07
Total revenues

14,377

13,452

12,273

11,448

10,763

9,703

6,932

5,516

5,048

4,716

4,377

4,097

3,171

Cost and expenses:
Cost of sales, excluding amortization and impairment of acquired intangible assets

1,955

1,816

1,630

1,478

1,240

1,171

857

545

466

400

382

401

335

Research and development

2,280

2,597

2,253

1,973

2,012

1,893

1,444

1,334

1,219

1,248

1,283

1,072

925

Selling, general and administrative

2,374

2,106

1,933

1,946

2,113

2,232

1,712

1,277

1,056

1,031

911

925

776

Amortization and impairment of acquired intangible assets

489

747

814

385

382

489

342

202

208

208

289

332

257

Collaboration profit (loss) sharing

241

185

112

10

0

0

85

317

317

258

215

136

14

Loss on divestiture of Hillerød, Denmark manufacturing operations

55

0

0

-

-

-

-

-

-

-

-

-

-

(Gain) loss on fair value remeasurement of contingent consideration

63

12

-62

-14

-30

38

0

-27

-36

0

-

-

-

Restructuring charges

1

12

0

33

93

0

0

2

19

75

-

-

-

Gain on dispositions, net

-

-

-

-

-

-

-

-

-

-

-

9

0

Acquired in-process research and development

0

112

120

0

0

-

-

-

-

244

-

25

84

TECFIDERA litigation settlement charge

-

-

-

454

0

0

-

-

-

-

-

-

-

Total cost and expenses

7,335

7,564

6,928

6,297

5,872

5,747

4,441

3,707

3,323

3,467

3,081

2,883

2,391

Gain on sale of rights

-

-

-

-

-

16

24

46

0

0

-

-

-

Income from operations

7,042

5,888

5,345

5,151

4,891

3,972

2,515

1,855

1,724

1,248

1,295

1,213

779

Other income (expense), net

83

11

-217

-218

-123

-25

-34

-0

-13

-18

37

-57

72

Income before income tax expense and equity in loss of investee, net of tax

7,125

5,899

5,128

4,933

4,767

3,946

2,480

1,855

1,711

1,229

1,332

1,155

852

Income tax expense

1,158

1,425

2,458

1,237

1,161

989

601

470

444

331

355

365

272

Equity in loss of investee, net of tax

-79

0

0

0

-12

-15

-17

-4

0

0

-

-

-

Net income

5,888

4,474

2,670

3,695

3,593

2,941

1,862

1,380

1,266

898

977

790

579

Net income (loss) attributable to noncontrolling interests, net of tax

0

43

131

-7

46

6

0

0

32

-106

6

6

-58

Net income attributable to Biogen Inc.

5,888

4,430

2,539

3,702

3,547

2,934

1,862

1,380

1,234

1,005

970

783

638

Net income per share:
Basic earnings per share attributable to Biogen Inc.

31.47

21.63

11.94

16.96

15.38

12.42

7.86

5.80

5.09

3.98

3.37

2.67

2.02

Diluted earnings per share attributable to Biogen Inc.

31.42

21.58

11.92

16.93

15.34

12.37

7.81

5.76

5.04

3.94

3.35

2.65

1.99

Weighted-average shares used in calculating:
Basic earnings per share attributable to Biogen Inc.

187

204

212

218

230

236

236

237

242

252

287

292

315

Diluted earnings per share attributable to Biogen Inc.

187

205

213

218

231

237

238

239

245

254

289

294

320

Product, net
Total revenues

11,379

10,886

10,354

9,817

9,188

8,203

5,542

4,166

3,836

3,470

3,152

2,839

2,136

Revenues from anti-CD20 therapeutic programs
Total revenues

2,290

1,980

1,559

1,314

1,339

1,195

1,126

1,137

996

1,077

1,094

1,128

926

Other
Total revenues

707

585

360

316

236

304

263

212

215

169

129

129

108